anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND AND OBJECTIVE: Patient-ventilator asynchrony (PVA) is associated with poor clinical outcomes and remains under-monitored. Automated PVA detection would enable complete monitoring standard observational methods do not allow. While model-based and machine learning PVA approaches exist, they have variable performance and can miss specific PVA events. This study compares a model and rule-based algorithm with a machine learning PVA method by retrospectively validating both methods using an independent patient cohort.
METHODS: Hysteresis loop analysis (HLA) which is a rule-based method (RBM) and a tri-input convolutional neural network (TCNN) machine learning model are used to classify 7 different types of PVA, including: 1) flow asynchrony; 2) reverse triggering; 3) premature cycling; 4) double triggering; 5) delayed cycling; 6) ineffective efforts; and 7) auto triggering. Class activation mapping (CAM) heatmaps visualise sections of respiratory waveforms the TCNN model uses for decision making, improving result interpretability. Both PVA classification methods were used to classify incidence in an independent retrospective clinical cohort of 11 mechanically ventilated patients for validation and performance comparison.
RESULTS: Self-validation with the training dataset shows overall better HLA performance (accuracy, sensitivity, specificity: 97.5 %, 96.6 %, 98.1 %) compared to the TCNN model (accuracy, sensitivity, specificity: 89.5 %, 98.3 %, 83.9 %). In this study, the TCNN model demonstrates higher sensitivity in detecting PVA, but HLA was better at identifying non-PVA breathing cycles due to its rule-based nature. While the overall AI identified by both classification methods are very similar, the intra-patient distribution of each PVA type varies between HLA and TCNN.
CONCLUSION: The collective findings underscore the efficacy of both HLA and TCNN in PVA detection, indicating the potential for real-time continuous monitoring of PVA. While ML methods such as TCNN demonstrate good PVA identification performance, it is essential to ensure optimal model architecture and diversity in training data before widespread uptake as standard care. Moving forward, further validation and adoption of RBM methods, such as HLA, offers an effective approach to PVA detection while providing clear distinction into the underlying patterns of PVA, better aligning with clinical needs for transparency, explicability, adaptability and reliability of these emerging tools for clinical care.
The invention discloses a kind of operating methods of Chinese medicine storage controlled atmosphere maintenance, and this method comprises the following steps: a. sweeps storehouse, determines medicinal material stack position size and location, keeps pile spacing appropriate；B. in gasket materials such as the old tarpaulin in logistics backing plate upper berth, burlap or plastic clothes；C. make and spread sealing counterdie；D. Chinese medicine pile is neatly convenient for air in pile to flow；E. overhead guard is made, the interface of counterdie and overhead guard should be stayed in away from 100~150cm of ground；F. pile top first spreads layer of plastic film, repaves one layer of piece of sack, air conditioning agent is placed on the piece of sack (1~3kg/m 3 ), it is last uniformly to place 4 empty cartons；G. overhead guard and counterdie are subjected to heat seal, pump most of air in medicine pile, finally sealed is evacuated aperture and completes the sealing of medicine pile；H. stack position registration card is filled in and hung, recording-related information is filled in.The operating method of Chinese medicine storage controlled atmosphere maintenance of the invention can be reduced or avoided during Chinese medicine storage it is mouldy damage by worms, ensure Chinese medicine quality and quality.
A single dose of active comparator will be administered to healthy male and female volunteers under fasting conditions before (treatment arm 2) or after (treatment arm 1) a wash-out interval of at least 7 days between the experimental drug administration. Reference formulation will be administered as a single dose of two 500 mg/30 mg tablets.
The composition of an extract of the Hippeastrum genus and its separate components is intended for the production of medicinal products and food supplements. The composition contains in weight %: galanthamine from 40 to 98, haemanthamine from 0.01 to 35, narwedine from 0.01 to 10, secondary alkaloids which can be of the homolycorine, and/or tazethyne, and/or montanine and/or galantamine, and/or haemanthamine and/or lycorine type from 0.01 to 35 and non-alkaloid plant metabolites from 0.001 to 1, derived from a total extract of the Hippeastrum genus. The content of alkaloids can range in weight % from 0.01 to 99 and of non-alkaloid plant metabolites and/or different inactive excipients and/or solvents respectively from 1 to 99.9. The composition can be in dry or liquid form. It finds an application for isolating pure compounds such as galanthamine and haemanthamine. 8 claims
STriatal-Enriched protein tyrosine Phosphatase (STEP) is a brain-specific tyrosine phosphatase that is associated with numerous neurological and neuropsychiatric disorders. STEP dephosphorylates and inactivates various kinases and phosphatases critical for neuronal function and health including Fyn, Pyk2, ERK1/2, p38, and PTPα. Importantly, STEP dephosphorylates NMDA and AMPA receptors, two major glutamate receptors that mediate fast excitatory synaptic transmission. This STEP-mediated dephosphorylation leads to their internalization and inhibits both Hebbian synaptic potentiation and homeostatic synaptic scaling. Hence, STEP has been widely accepted to weaken excitatory synaptic strength. However, emerging evidence implicates a novel role of STEP in neuronal hyperexcitability and seizure disorders. Genetic deletion and pharmacological blockade of STEP reduces seizure susceptibility in acute seizure mouse models and audiogenic seizures in a mouse model of Fragile X syndrome. Pharmacologic inhibition of STEP also decreases hippocampal activity and neuronal intrinsic excitability. Here, we will highlight the divergent roles of STEP in excitatory synaptic transmission and neuronal intrinsic excitability, present the potential underlying mechanisms, and discuss their impact on STEP-associated neurologic and neuropsychiatric disorders.
Gestational diabetes mellitus (GDM) is a high blood glucose (hyperglycemia) first occurring or first recognized during pregnancy, it is affecting 16.4% of women globally and 36.6 % in this region. It is consistent, strong evidence on the impact of GDM on short and long term health impacts on both mother and her child, thereby presenting significant challenges to acute care and public health. Currently, our understanding of strategies that are effective in preventing GDM is limited. Indeed, prospective studies have indicated a positive result of lifestyle intervention on preventing the risk of GDM in pregnant women but we lack consistency in the findings from randomized controlled trials (RCT). Moreover, most of these trials have been reported from developed countries and none of them were presented from this region. In the present project, we aim to determine whether GDM can be prevented by a 12-week moderate lifestyle intervention compared with usual standard care in high-risk pregnant women. In addition, we will also examine maternal pregnancy and birth outcomes. If the results show a positive association, we could develop this as a clinical process for improving patient care and cost.

This is a randomized controlled trial where participants will be included if they have more than one risk factors for GDM and randomized to two arms moderate-intensity lifestyle intervention (LI) or usual standard care group (control)(UC) between 6-12 gestational week. For the intervention group, standardized 12- week program and would be delivered in 4 sessions (2 individual, 2 telephonic) by a licensed dietitian. This lifestyle modification program is designed to achieve targeted weight gain and improve glycemic control through a combination of diet therapy, increased daily physical activity, and behavioral modification. The UC participants will receive no session as per the usual clinic protocol. Follow-up until l 24-28 gestational weeks, and the incidence of GDM was used to evaluate the effect of the intervention. At the end of interventions, participants in both arms will receive usual care based on their diagnosis and discretion of their physician. A sample size of 70 participants in each arm was estimated to give the power of 80%.
The invention relates to a novel elongase gene comprising the sequences cited in sequence SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 and SEQ ID NO:7 or to homologues, derivatives or analogues thereof. The invention also relates to a gene construct containing these genes or homologues, derivatives or analogues thereof, and to its use. The invention additionally relates to the vectors or transgenic organisms containing an elongase gene comprising the sequence SEQ  ID NO:1, SEQ ID NO:3, SEQ ID NO:5 and SEQ ID NO:7 or containing homologues, derivatives or analogues thereof. The invention relates to the use of the elongase sequences alone or in combination with additional elongases and/or with additional fatty acid biosynthesis genes. The invention relates to a novel elongase gene comprising the sequence SEQ ID NO:1 or to homologues, derivatives or analogues thereof. The invention also relates to a method for producing multiple-unsaturated fatty acids and to a method for introducing DNA  into organisms which produce large quantities of oils and, in particular, oils having a high content of unsaturated fatty acids. The invention further relates to an oil and/or to a fatty acid preparation having a high content of multiple-unsaturated fatty acids that contain at least two double bonds and/or to a triacylglycerin preparation having a high content of multiple-unsaturated fatty acids that contain at least two double bonds.
PROBLEM TO BE SOLVED: To obtain the subject remedy capable of remarkably improving canine intractable dermatitis by including canine interferon-γ as an active ingredient. SOLUTION: This remedy contains canine interferon-γ (canine INF-γ). As the canine INF-γ, e.g. a polypeptide having the amino acid sequence expressed by the formula is included. A canine INF-γ produced through a gene recombinant technique is economically preferable. The canine INF-γ produced through the gene recombinant technique is produced by use of, e.g. host cells or a host animal, such as E. coli, transferred with a gene encoding the amino acid sequence expressed by the formula according to a known method. A dose of 0.0.02-1M unit of canine INF-γ per 1 kg of body weight per time is preferable. The administration is preferably conducted 2-10 times at a 1-7 day interval. As an administration method, subcutaneous injection is preferable because of its simplicity, mitigating a burden on sick dogs and affording high therapeutic efficacy.
PURPOSE:To obtain an antiviral agent, containing a suitably processed Vigna angularis, an antiviral agent containing the Vigna angularis and an extracted essence of Rosa roxburghii Tratt. in combination or an antiviral agent using the Vigna angularis, the extract of the Rosa roxburghii Tratt. and a grape pigment in combination. CONSTITUTION:This antiviral agent contains Vigna angularis such as a powder of the Vigna angularis or an extract essence thereof as an active ingredient. Excellent antiviral properties of the Vigna angularis are utilized to use the Vigna angularis as a feed or a functional food. In this case, the content of the extract essence of the Vigna angularis is 0.01-5%, preferably about 0.05-3%. Antiviral activities are enhanced by adding an extract essence of Rosa roxburghii Tratt. without manifesting the antiviral actions itself to the antiviral agent containing the Vigna angularis. A grape pigment, together with the extract essence of Rosa roxburghii Tratt., is added to provide a better antiviral agent.
The invention discloses a lucid ganoderma anti-aging cream and a preparation method thereof, wherein the preparation method comprises the following steps: emulsifier, glycerin, butanediol, preservative, ganoderma lucidum polysaccharide derivative, furan lignan, selenium-enriched protein, ganoderma lucidum, ganoderma capense and deionized water. The ganoderan has effects of resisting aging by reducing free radicals and improving enzyme activity and immunity. The ganoderan can also improve cell proliferation index, change expression level related to skin cell aging, and make ganoderan have anti-epidermal aging effect. The selenium-enriched protein also enables the organism to better absorb selenium, so that the antioxidase is synthesized more quickly. The furan lignan structure has phenolic hydroxyl, and can show remarkable antioxidant activity. The anti-aging ganoderma lucidum facial cream disclosed by the invention can achieve the anti-aging effect to the greatest extent on the basis of the moisturizing and water replenishing effects.
Day 1 (Period 1): participants will receive a single dose of two sitagliptin/metformin XR tablets with a low- to moderate-fat meal (breakfast). Days 2-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.
Chronic subdural hematomas are a common problem faced by neurosurgery with an annual incidence of 13.5/100,00 persons per year and up to 58/100,000 in the over 65 years old population. Their treatment is often complicated by recurrence with rates reported as high as 33%. Currently there is no good strategy to help avoid this problem, which adds significantly to patient morbidity. The pathogenesis of this problem is believed to be related to the propensity of the associated neo-membranes to bleed. It has been shown with labeled red blood cells that bleeding continues to occur into the hematoma cavity. It has also been shown that there are high levels of tissue plasminogen activator in the outer membrane of chronic subdural hematomas. It has been found that ratio of tissue plasminogen activator to plasminogen activator inhibitor contributed to the pathogenesis. It has also been shown that chronic subdural hematomas have high levels of fibrin degradation products which in addition to marking the breakdown of fibrin are themselves antihemostatic by enhancing tissue plasminogen activator activity, having an antithrombin affect and inhibiting platelet aggregation and fibrin polymerization. Essentially, a scenario of ongoing hemorrhage and repeated clot formation and hyperfibrinolysis leads to the expansion and recurrence of chronic subdural hematomas.

Given the importance of plasmin and hyperfibrinolysis in the pathophysiology of chronic subdural hematomas, interrupting its action and the vicious cycle it propagates seems an ideal therapeutic target. Tranexamic acid is a synthetic lysine amino acid derivative. It binds to the fibrin binding sites on plasmin or plasminogen and prevents its interaction and degradation of fibrin. This effect on the neo-membranes of chronic subdural hematomas should prevent rebleeding and the reaccumulation of the subdural hematoma.

Tranexamic acid has been shown to be safe and effective in reducing blood loss and transfusions in a number of types of surgery, reduced mortality and need for urgent surgery in patients with GI bleeding, and reduced bleeding associated with menorrhagia and pregnancy. Adverse effects are generally mild. Thought there is a theoretical increased risk of thromboembolic complications, multiple randomized controlled trials have not shown an increased risk. Furthermore, in a study of over 3000 gynecologic patients using tranexamic acid, there were no thromboembolic complications. This is likely because tranexamic acid has been shown to not have an effect on plasminogen in the vein wall.
Cosmetic or dermatological preparations which are finely disperse systems of the water-in-oil type, comprising1. an oil phase,2. a water phase,3. a combination ofa) at least one modified phyllosilicateb) and boron nitride, where both the modified phyllosilicate or phyllosilicates and the boron nitride exhibit both hydrophilic and lipophilic properties, i.e. have amphiphilic character and position themselves at the water/oil interface and4. at most 0.5% by weight of one or more emulsifiers andoptionally comprising further cosmetic or pharmaceutical auxiliaries, additives and/or active ingredients.
1338151 Encapsulation method FUJI PHOTO FILM CO Ltd and TOYO JOZO CO Ltd 19 April 1971 [3 Feb 1970] 21232/71 Heading B8C Microcapsules are made by dissolving a filmforming polymer in a solvent having a dielectric constant between 10 and 40 and being insoluble or only sparingly soluble in a mineral or silicone oil, dispersing a (solid or liquid) core material in the solution and dispersing the resultant in the mineral or silicone oil in the form of fine droplets. Thereafter, the solvent is caused to evaporate, e.g. by gentle heating, and the polymer encapsulates the core material. Suitable solvents are: NeOH, EtOH, iso-PrOH, BuOH, benzyl alcohol, ethylene glycol, propylene glycol, phenol, acetone, acetic anhydride, nitromethane and ethylene diamine. Suitable polymers include cellulose esters and ethers, shellac, P.V.P., polyvinyl alcohol, acrylic and methacrylic polymers and co-polymers, styrene/ maleic anhydride copolymers and gelatin/ alkyl sulphate complexes. The core material may be an enzyme or a chemical, e.g. tolylene diamine HCL or Na2CO3.
Post Isometric Relaxation Group (PIRG) participants will perform a PSSE with post isometric relaxation (PIR) technique, Isolytic Stretching Group (ISG) participants will perform a PSSE with isolytic stretching technique and Static Stretching Group Group (SSG) participants will perform a PSSE with static stretching technique. All exercises will be performed in the modified cross-body position. Subacromial space and posterior capsule thickness will be measured using a 7-12 MHz linear transducer with USG (LOGIQ e Ultrasound, GE Healthcare, USA). Athletes' GIRD results and rotational ROM measurements will be measured and recorded using a bubble inclinometer (Fabrication End Inc, New York, USA). The upper extremity functional performance of the athletes will be evaluated with the Functional Throwing Performance Index (FTPI). Evaluations will be repeated tree times before, after the stretching exercise and 30 minutes later and the effects of different muscle energy techniques (MET) will be compared. Investigators hypothesized PSSE made with different MET techniques have different effects on Acromio-Humeral Distance, posterior capsule thickness, rotational ROM measurements and performance on overhead athletes with GIRD and the effects of MET would be superior to static stretching.
To prepare infusion solutions, dilute 1 mL of PROSTIN VR PEDIATRIC Sterile Solution with Sodium Chloride Injection USP or Dextrose Injection USP. Undiluted PROSTIN VR PEDIATRIC Sterile Solution may interact with the plastic sidewalls of volumetric infusion chambers causing a change in the appearance of the chamber and creating a hazy solution. Should this occur, the solution and the volumetric infusion chamber should be replaced.

When using a volumetric infusion chamber, the appropriate amount of intravenous infusion solution should be added to the chamber first. The undiluted PROSTIN VR PEDIATRIC Sterile Solution should then be added to the intravenous infusion solution, avoiding direct contact of the undiluted solution with the walls of the volumetric infusion chamber.

Dilute to volumes appropriate for the pump delivery system available. Prepare fresh infusion solutions every 24 hours. Discard any solution more than 24 hours old.
Chronic pain (CP) significantly impacts quality of life and increases noncommunicable disease risk, with recent U.S. data showing a 6.3% incidence rate, surpassing diabetes, depression, and hypertension. International studies suggest higher mortality in CP populations, yet prior U.S. data are inconclusive. To investigate CP's mortality risk, we analyzed National Health Interview Survey and National Death Index data. We hypothesized that individuals with CP and high-impact CP (HICP [≥1 activity limitation]) would exhibit higher mortality rates. National Health Interview Survey provided demographics, pain reporting, lifestyle, and psychosocial data matched with National Death Index mortality records. Chi-square analyses explored the relationships between CP/HICP and demographics, lifestyle factors, psychosocial variables, and mortality. Cox proportional hazards models assessed mortality risk between groups. The weighted sample was 245,899,776; 20% reported CP and 8% HICP, both groups exhibiting higher mortality rates than pain-free individuals (CP: 5.55%, HICP: 8.79%, total: 2.82%). Hazard ratios indicated nearly double the mortality risk for CP and 2.5 times higher risk for HICP compared to those without these conditions. Adjusting for lifestyle and psychosocial factors reduced mortality risk but remained elevated compared with non-CP individuals. Heart disease, malignant neoplasms, and chronic lower respiratory diseases accounted for a higher percentage of deaths in CP cases. CP individuals showed higher rates of smoking, alcohol consumption, obesity, inactivity, depression, anxiety, emotional problems, and sleep disturbances. CP and HICP significantly influence mortality outcomes, leading to excess deaths compared with pain-free individuals. Given the relationship between pain, lifestyle, psychosocial variables, and mortality, further investigations are needed into CP causation and prevention strategies. PERSPECTIVE: This article presents evidence regarding the relationship between CP, HICP, and mortality. Additional findings are discussed regarding the impact of demographics, lifestyle, and psychosocial variables on mortality in those with versus without CP and HICP. These findings are crucial for informing future research, prevention, and healthcare management strategies.
<P>PROBLEM TO BE SOLVED: To easily process data related to diagnostic records written in a medical document.  <P>SOLUTION: An examination card 12 is the medical document into which diagnostic records are written. On the examination card 12, an encoded pattern formed by encoding coordinates is printed. A digital pen 17 reads the encoded pattern, reads strokes of the pen tip, and transmits stroke data to a client terminal 16. The client terminal 16 receives the stroke data and digitizes the written diagnostic records. Further, the client terminal 16 detects a predetermined action of the digital pen 17 on the examination card 12 on the basis of the stroke data to accept the action as a command, and performs data processing related to diagnostic record data such as retrieving and reading data related to the diagnostic records.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Prepn. of a solid shaped article carrying a predetermined unit quantity of a chemical (I) comprises first adding to a mould a compsn. comprising the predetermined amt. of (I) and a soln. of a carrier material (II) inert towards (I).  The side wall or walls of the mould diverge outwards from the base and make an angle with the vertical of at least 5 degrees at the surface of the compsn.. The mean depth of the cmpsn. in the mould is 4.0mm or less.  The compsn. is frozen in the mould, and then the solvent is sublimed from the frozen compsn. so as to produce a network of (II) carrying (I).